192 related articles for article (PubMed ID: 36511458)
1. Tumor-induced osteomalacia treated with T12 tumor resection.
Mancini AJ; Sabet A; Nielsen GP; Parker JA; Schwab JH; Ward A; Wu JS; Malabanan AO
Endocrinol Diabetes Metab Case Rep; 2022 Dec; 2022():. PubMed ID: 36511458
[TBL] [Abstract][Full Text] [Related]
2. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
[TBL] [Abstract][Full Text] [Related]
3. Hiding in plain sight: Gene panel and genetic markers reveal 26-year undiagnosed tumor-induced osteomalacia of the rib concurrently misdiagnosed as X-linked hypophosphatemia.
Colazo JM; DeCorte JA; Gillaspie EA; Folpe AL; Dahir KM
Bone Rep; 2021 Jun; 14():100744. PubMed ID: 33490314
[TBL] [Abstract][Full Text] [Related]
4. Phosphaturic Mesenchymal Tumor in the Proximal Femur Presenting as Tumor-induced Osteomalacia: A Case Report and Literature Review.
Tungenwar S; Subith S; Mukadam M; Kokate S; Gunay S
J Orthop Case Rep; 2024 Feb; 14(2):23-28. PubMed ID: 38420233
[TBL] [Abstract][Full Text] [Related]
5. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
6. Tumor induced osteomalacia - A long way toward correct diagnosis and management.
Filipová L; Zikán V; Krsek M; Netuka D; Michal M; Lazúrová I
Bone Rep; 2022 Jun; 16():101180. PubMed ID: 35281212
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced osteomalacia.
Florenzano P; Gafni RI; Collins MT
Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
[TBL] [Abstract][Full Text] [Related]
8. Phosphaturic mesenchymal tumor with
Dwabe S; Chow W
Ther Adv Med Oncol; 2024; 16():17588359241232092. PubMed ID: 38455709
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria.
Velazquez-Navarro JA; Loya-Teruel E; Rios-Gomez M; Montes-Ramirez JE
Cureus; 2022 Jan; 14(1):e20893. PubMed ID: 35145798
[TBL] [Abstract][Full Text] [Related]
10. A Rare Association Between Osteomalacia, Phosphaturic Mesenchymal Tumor, and Ovarian Cancer: A Case Report and Literature Review.
Mazza M; Arcidiacono GP; Hoxhaj I; Padoan V; Tasca G; Burei M; Sella S; Simioni P; Giannini S; Mocellin S
Calcif Tissue Int; 2024 May; ():. PubMed ID: 38806758
[TBL] [Abstract][Full Text] [Related]
11. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
12. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
Abate V; Vergatti A; De Filippo G; Damiano V; Menale C; D'Elia L; Rendina D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1006-e1011. PubMed ID: 38006315
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Induced Osteomalacia.
Florenzano P; Hartley IR; Jimenez M; Roszko K; Gafni RI; Collins MT
Calcif Tissue Int; 2021 Jan; 108(1):128-142. PubMed ID: 32504138
[TBL] [Abstract][Full Text] [Related]
15. Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature.
Adnan Z; Nikomarov D; Weiler-Sagie M; Roguin Maor N
Endocrinol Diabetes Metab Case Rep; 2019 May; 2019():. PubMed ID: 31051470
[TBL] [Abstract][Full Text] [Related]
16. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
Ghorbani-Aghbolaghi A; Darrow MA; Wang T
Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
[TBL] [Abstract][Full Text] [Related]
17. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
Hartley IR; Roszko KL; Li X; Pozo K; Streit J; Del Rivero J; Magone MT; Smith MR; Vold R; Dambkowski CL; Collins MT; Gafni RI
JBMR Plus; 2022 Aug; 6(8):e10661. PubMed ID: 35991529
[TBL] [Abstract][Full Text] [Related]
18. Phosphaturic mesenchymal tumor-induced bilateral osteomalacia femoral neck fractures: a case report.
Zhang Y; Hu M; Guo C; Yang X; Xiang S; Xu H
Front Endocrinol (Lausanne); 2024; 15():1373794. PubMed ID: 38689735
[TBL] [Abstract][Full Text] [Related]
19. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
20. An intracranial mass causing tumor-induced osteomalacia (TIO): Rapid and complete resolution of severe osteoporosis after surgical resection.
Colazo JM; Thompson RC; Covington NV; Dahir KM
Radiol Case Rep; 2020 May; 15(5):492-497. PubMed ID: 32140194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
